The expanding utilization of PSMA-PET-CT has revealed PSMA-ligand uptake in other tissues/conditions, including normal nonprostatic epithelial cells, inflammation/infection, nonprostatic neoplastic cells, and tumor-associated neovasculature.1As exemplified by this case, it is important to investigate unusual sites of uptake on PSMA-PET-CT to exclude synchronous tumors. This evidence concerns the gene FOLH1 and infection.